A Promising Future for Treating Multiple Myeloma with Bispecific Antibodies
Jun 25, 2022 Speakers
Donna Catamero, ANP-BC, OCN, CCRC (The Mount Sinai Health System, IMF Nurse Leadership)
Tom Martin, MD (University of California San Francisco)
What to Expect
To ensure patients and care partners better understand the promising future in bispecific therapies, please tune in to this Live Webinar to hear from myeloma experts as they cover key questions, concerns, and highlights.
Through this virtual seminar, you will learn more and gain a better understanding of the following:
What is Immunotherapy?
What are monoclonal antibodies?
What is CAR T-cell therapy?
What are Bispecific Antibodies and how do they work? o Are there different types of Bi-specifics?
How are bi-specific therapies administered?
What are the advantages of bi-specific therapies? o What are the side effects of bi-specifics and how are side effects managed?
Can they be administered in combination?
Where in the treatment paradigm will they be used?
_______________
Improving Lives ' Finding the Cure
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Jun 25, 2022 Speakers
Donna Catamero, ANP-BC, OCN, CCRC (The Mount Sinai Health System, IMF Nurse Leadership)
Tom Martin, MD (University of California San Francisco)
What to Expect
To ensure patients and care partners better understand the promising future in bispecific therapies, please tune in to this Live Webinar to hear from myeloma experts as they cover key questions, concerns, and highlights.
Through this virtual seminar, you will learn more and gain a better understanding of the following:
What is Immunotherapy?
What are monoclonal antibodies?
What is CAR T-cell therapy?
What are Bispecific Antibodies and how do they work? o Are there different types of Bi-specifics?
How are bi-specific therapies administered?
What are the advantages of bi-specific therapies? o What are the side effects of bi-specifics and how are side effects managed?
Can they be administered in combination?
Where in the treatment paradigm will they be used?
_______________
Improving Lives ' Finding the Cure
In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.
Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF's reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
